Shares of BioNTech, the German company that collaborated with Pfizer to develop a Covid-19 vaccine, experienced a decline in early trading on Monday due to lower-than-expected second-quarter revenue.
During the quarter, the company reported revenue of €168 million ($184 million), falling significantly short of the €692 million projected by analysts on FactSet and a substantial decrease from the €3.2 billion in sales from the same period last year. BioNTech attributed this decline to write-offs by Pfizer, which had a significant impact on the profit share and consequently affected earnings.
In premarket trading, American depositary receipts of BioNTech (ticker: BNTX) dropped by 5% to $101.18. Over the past year, the company's shares have fallen by more than 40%.
Although BioNTech reported a loss of €0.79 per share for the quarter, it was narrower than the estimated €0.92 per share.
Jens Holstein, the chief financial officer, stated, "We enter the second half of 2023 with a strong financial position, on track to launch our new variant-adapted Covid-19 vaccine. The Covid-19 vaccine market remains highly dynamic and difficult to fully predict."
Indonesia's Economy Beats Expectations
European Stocks Close Flat
Our Latest News
Higher Rates and Tighter Financial Conditions Impact U.S. Commercial Mortgage Market
The U.S. commercial mortgage market is facing challenges due to higher rates and tighter financial conditions, leading to an increase in delinquencies. Office l...
Yelp Reports Strong Quarterly Results
Yelp Inc. reports strong quarterly results, exceeding analysts' estimates, with record-breaking net revenue and positive future projections.
DraftKings Position for Success
Barclays upgrades DraftKings, highlighting market potential and recent developments. Company well-positioned for growth in digital gaming sector.